Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
48.00    3.50 (7.87%)
Bid:
47.50
Ask:
48.50
Spread: 1.00 (2.105%)
Market Cap: £92.09m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

H1 2025 Update

17 Jul 2025 07:00

RNS Number : 3888R
Iofina PLC
17 July 2025
 

 17 July 2025

 

Iofina plc

("Iofina", the "Company" or the "Group")

(AIM: IOF)

 

H1 2025 Corporate Update

Another Record H1 Production

IO#11 Commissioned

 

Iofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, today provides an update to the market regarding its activities during H1 2025 (the "Period") and the commissioning of IO#11.

 

The Company is pleased to report that following a strong second quarter, Iofina Resources produced 305.5 metric tonnes ("MT") of crystalline iodine in the Period, an increase of 10.6% (H1 2024: 276.1 MT). This figure was both a record H1 production total and slightly higher than the Company's revised production guidance for the Period of c.300 MT, as stated in the Q1 2025 update. 

 

Iofina's Resources' newest commissioned plant, IO#11, is in the final stages of hydro-testing, with brine water flowing through the system. Iofina expects the new plant to be producing crystalline iodine this month. IO#11 will be the third plant in operation in the central Oklahoma core area since June 2023, with the Group having eight IOsorb® plants in total. IO#11 is expected to make a material contribution to total crystalline iodine production in the second half of the year, with an estimated annual output from this plant of approximately 100 MT.

 

The Company is finalising the specific location and timeline with its preferred partner for IO#12, with the intention of commencing foundation work on the new plant before the end of 2025.

 

With the Company's plants operating at a more optimal flow rate compared to the start of the year and the addition and ramp-up of IO#11 in Q3 2025, the Company anticipates production in the second half of 2025 to be in the range of 400-440 MT from our eight operating plants in Oklahoma. As IO#11 production normalises, this total H2 2025 production range will become clearer over the coming months, and we will update the market at that point.

 

Iofina continues to see strong demand for its products, with sales tracking in line with the Board's expectations and reflecting the favourable trends across the iodine market. The price of spot iodine (100% basis) is firmly above $70/kg and is expected to stay at these levels for the foreseeable future.

 

Finally, the Company continues to preserve its safety record, with no lost time accidents for over four years. The Group continually seeks to implement the latest policies, with safety being the paramount factor.

 

 

 

Commenting, President and CEO, Dr. Tom Becker, stated:

"After experiencing some initial production challenges in the first quarter of the year, our team has successfully worked with our brine supply partners to improve water flows to the plants, culminating in a record H1 production of 305.5MT. We are also pleased to have completed IO#11 on time and on budget, and with production at the new plant expected to ramp up during Q3 2025, we now anticipate producing 400-440 MT of crystalline iodine during the second half of 2025. The execution of our growth strategy, combined with a healthy iodine market, will result in 2025 seeing further records for the Group."

 

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.

 

 

Enquiries:

 

Iofina plc 

Dr. Tom Becker

CEO & President

Tel: +44 (0)20 3006 3135

 

Nomad & Broker:

Canaccord Genuity Limited

Henry Fitzgerald-O'Connor/Harry Rees

Tel: +44 (0)20 7523 8000

 

Media Contact:

Yellow Jersey PR Limited

Charles Goodwin/Shivantha Thambirajah/Zara McKinlay

Tel: +44 (0)7747 788 221/+44 (0)7983 521 488

About Iofina:

Iofina plc (AIM: IOF) is a vertically integrated company that specialises in the production of Iodine and the manufacturing of specialty chemical products. Iofina is the second largest producer of iodine in North America and operates the manufacturing entities Iofina Resources and Iofina Chemical.

LEI: 213800QDMFYVRJYYTQ84

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns, and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina currently operates five producing IOsorb® plants in Oklahoma and is consistently using technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high quality halogen speciality chemicals derived from raw iodine, as well as non-iodine-based products. Iofina Chemical celebrated its 40th anniversary in 2023 as a preeminent halogen-based specialty chemicals company.

www.iofina.com

 

Follow Iofina's latest developments via its LinkedIn and X accounts.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFLFEADLIRLIE
Date   Source Headline
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company
17th Jan 20229:00 amRNSPrice Monitoring Extension
17th Jan 20227:00 amRNSQ4 2021 Update
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
29th Dec 20217:00 amRNSBusiness Update
20th Oct 202112:44 pmRNSHolding(s) in Company
15th Oct 20217:00 amRNSQ3 2021 Update
12th Oct 20218:47 amRNSHolding(s) in Company
24th Sep 20217:00 amRNSInterim Results
23rd Sep 20214:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.